Stay updated on Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Sign up to get notified when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.

Latest updates to the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page
- Check6 days agoChange DetectedRevision label updated to v3.3.2; no study content or functionality changes are indicated.SummaryDifference0.1%

- Check13 days agoChange DetectedThe changes are minor wording adjustments regarding how PubMed publications are displayed, along with a page version revision tag. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the government funding lapse notice from the page; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedNo additions or deletions were observed between the old and new versions of the page.SummaryDifference0.4%

- Check63 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%

- Check70 days agoChange DetectedPage updated to version v3.1.0 and removed multiple drug-safety related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) with no new substantive content added.SummaryDifference0.4%

Stay in the know with updates to Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.